Stephen J. Haggarty

This study identifies INMT's localization near the Golgi apparatus in human neurons and suggests it creates a region for psychedelic tryptamine biosynthesis.

The paper identifies a druggable groove on DeltaFOSB that allows small molecules to modulate its DNA binding and release, with one compound reducing genomic occupancy by 60% in vivo.

This paper demonstrates the creation of YL0441, a highly effective inhibitor of DeltaFOSB that reduces genomic DNA binding sites by ~94% in APP mice.

Discovery of SMCs that correct MAPT splicing, reduce 4R tau, and rescue pathology in patient-derived neuronal and in vivo models of 4R tauopathies.

This study identifies genetic risk factors for FTLD-TDP subtypes using whole-genome sequencing and meta-analysis across multiple cohorts.

This study shows that cholesterol dysregulation promotes tau aggregation in patient-derived neurons and demonstrates that tau degraders can block this effect.

The paper develops a scalable cortical organoid platform with quality control metrics and identifies early dysregulation of phosphatase and prefoldin genes in FTD-tau neurons.

The paper identifies small molecule inducers of miR-132 in human iPSC-derived neurons using HTS-HTS, showing neuroprotective effects against neurodegenerative phenotypes.

This study shows that deleting GIT1 in the brain impairs cognition and disrupts phosphorylation networks of synaptic proteins linked to schizophrenia and neurodevelopmental disorders.

This study shows that reducing tau with a degrader prevents mitochondrial fragmentation and oxidative stress in ALS models.

This study identifies TNIK-mediated phosphorylation sites on Arc protein, showing their role in regulating Arc's subcellular distribution and self-assembly, linking Arc and TNIK in neuronal function and psychiatric disorders.

This study shows that glutamatergic dysfunction occurs before neuron loss in cerebral organoids with MAPT mutations, suggesting therapeutic targets for FTD.

This study identifies and characterizes a novel 44-mer peptide from DISC1 that inhibits GSK3β in a non-competitive manner, offering a new approach for developing selective GSK3β inhibitors.

The paper identifies a Cdk5-derived peptide that inhibits Cdk5/p25 activity and reduces neurodegenerative phenotypes in cellular and animal models.

This study shows that disrupting the ANK3 gene in mice affects microtubule dynamics via GSK3/CRMP2 signaling, linking it to psychiatric illness mechanisms.

The paper introduces the L1000 platform, a high-throughput gene expression profiling method, and reports 1.3 million perturbational profiles expanding the Connectivity Map for drug mechanism discovery and functional annotation.